ORIC Q4 2024 Earnings — ORIC Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ORICORIC Pharmaceuticals, Inc.

$1B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$304,000

Operating Income

-$40M

Net Income

-$36M

EPS (Diluted)

$-0.51

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$274M

Total Liabilities

$31M

Stockholders' Equity

$243M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$304,000	-$263,000	-15.6%
Operating Income	-$40M	-$31M	-25.9%
Net Income	-$36M	-$28M	-28.2%